Johansson Eva, Engervall Per, Landgren Ola, Grimfors Gunnar, Widell Susanne, Rezai Shahideh, Björkholm Magnus
Department of Medicine, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden.
Eur J Haematol. 2006 Jul;77(1):61-6. doi: 10.1111/j.1600-0609.2006.00665.x. Epub 2006 Mar 27.
Splenectomy may lead to a good response in 60-80% of adult patients with corticosteroid refractory idiopathic thrombocytopenic purpura (ITP) but, the long-term response to splenectomy still remains less well defined. We assessed the long-term efficacy and safety of splenectomy in adult patients with chronic ITP. A cohort of 59 splenectomised ITP patients (M/F = 25/34; median age 39 yr; range 14-75) were followed up for a median of 18 yr (range 2-32). No life-threatening surgical complications were observed. The overall response rate was 78% with 59% complete remission (CR) and 19% partial remission (PR). CR and PR patients were younger than non-responding patients at time of diagnosis (median age: 36 yr vs 48 yr, P = 0.03) and at splenectomy (median age: 38 yr vs 51 yr, P = 0.02). Among the 46 responding patients, eventually 17 had relapse. No disease progression occurred after 12.1 and 7.3 yr for patients in CR or PR, respectively. One case of fatal septicaemia was recorded. We conclude that splenectomy is an effective and safe treatment in adult patients with chronic ITP failing to respond to corticosteroid treatment and importantly, our findings support the view that response to splenectomy is durable after a certain point in time.
脾切除术可能使60%-80%的成年糖皮质激素难治性特发性血小板减少性紫癜(ITP)患者获得良好反应,但脾切除术的长期反应仍不太明确。我们评估了脾切除术对成年慢性ITP患者的长期疗效和安全性。对59例接受脾切除术的ITP患者(男/女=25/34;中位年龄39岁;范围14-75岁)进行了中位时间为18年(范围2-32年)的随访。未观察到危及生命的手术并发症。总缓解率为78%,其中完全缓解(CR)率为59%,部分缓解(PR)率为19%。CR和PR患者在诊断时(中位年龄:36岁对48岁,P=0.03)和脾切除时(中位年龄:38岁对51岁,P=0.02)比未缓解患者年轻。在46例缓解患者中,最终有17例复发。CR或PR患者分别在12.1年和7.3年后未发生疾病进展。记录到1例致命性败血症。我们得出结论,脾切除术对于对糖皮质激素治疗无反应的成年慢性ITP患者是一种有效且安全的治疗方法,重要的是,我们的研究结果支持这样一种观点,即脾切除术后在一定时间点后的反应是持久的。